David Nittner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Nittner has a total of 232 co-authors. Here are the top co-authors by number of shared publications:
Elise Bonvin
15 shared publicationsEmilie Calonne
15 shared publications- Enrico Radaelli
University of Pennsylvania, Philadelphia, PA
15 shared publications Flavie Luciani
15 shared publicationsLionel Larue
15 shared publicationsMartin Bizet
15 shared publications
Latest Publications
- Open Access
- 5 February 2026
- Published by Springer Nature in Nature
- Vol. 650 (8103) , E24
Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis
- 5 February 2026
- Published by Springer Nature in Nature
- Vol. 650 (8103) , E24
Open AccessAuthor Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis
- Top Cited PapersOpen Access
- 16 September 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (9) , 1-20
BDH2-driven lysosome-to-mitochondria iron transfer shapes ferroptosis vulnerability of the melanoma cell states
Iron sustains cancer cell plasticity, yet it also sensitizes the mesenchymal, drug-tolerant phenotype to ferroptosis. This posits that iron compartmentalization must be tightly regulated. However, the molecular machinery governing organelle Fe(II) compartmentalization remains elusive. Here, we show that BDH2 is a key effector of inter-organelle Fe(II) redistribution and ferroptosis vulnerability during melanoma transition from a melanocytic (MEL) to a mesenchymal-like (MES) phenotype. In MEL cells, BDH2 localizes at the mitochondria–lysosome contacts (MLCs) to generate the siderophore 2,5-dihydroxybenzoic acid (2,5-DHBA), which ferries iron into the mitochondria. Fe(II) transfer by BDH2 supports mitochondrial bioenergetics, which is required to maintain lysosomal acidification and MLC formation. Loss of BDH2 alters lysosomal pH and MLC tethering dynamics, causing lysosomal iron sequestration, which primes MES cells for ferroptosis. Rescuing BDH2 expression, or supplementing 2,5-DHBA, rectifies lysosomal pH and MLCs, protecting MES cells from ferroptosis and enhancing their ability to metastasize. Thus, we unveil a BDH2-dependent mechanism that orchestrates inter-organelle Fe(II) transfer, linking metabolic regulation of lysosomal pH to the ferroptosis vulnerability of the mesenchymal, drug-tolerant cancer cells.
- 16 September 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (9) , 1-20
Top Cited PapersOpen AccessBDH2-driven lysosome-to-mitochondria iron transfer shapes ferroptosis vulnerability of the melanoma cell states
Iron sustains cancer cell plasticity, yet it also sensitizes the mesenchymal, drug-tolerant phenotype to ferroptosis. This posits that iron compartmentalization must be tightly regulated. However, the molecular machinery governing organelle Fe(II) compartmentalization remains elusive. Here, we show that BDH2 is a key effector of inter-organelle Fe(II) redistribution and ferroptosis vulnerability during melanoma transition from a melanocytic (MEL) to a mesenchymal-like (MES) phenotype. In MEL cells, BDH2 localizes at the mitochondria–lysosome contacts (MLCs) to generate the siderophore 2,5-dihydroxybenzoic acid (2,5-DHBA), which ferries iron into the mitochondria. Fe(II) transfer by BDH2 supports mitochondrial bioenergetics, which is required to maintain lysosomal acidification and MLC formation. Loss of BDH2 alters lysosomal pH and MLC tethering dynamics, causing lysosomal iron sequestration, which primes MES cells for ferroptosis. Rescuing BDH2 expression, or supplementing 2,5-DHBA, rectifies lysosomal pH and MLCs, protecting MES cells from ferroptosis and enhancing their ability to metastasize. Thus, we unveil a BDH2-dependent mechanism that orchestrates inter-organelle Fe(II) transfer, linking metabolic regulation of lysosomal pH to the ferroptosis vulnerability of the mesenchymal, drug-tolerant cancer cells.
- Open Access
- 18 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (42) , eadp6164
Secreted Apoe rewires melanoma cell state vulnerability to ferroptosis
A major therapeutic barrier in melanoma is the coexistence of diverse cellular states marked by distinct metabolic traits. Transitioning from a proliferative to an invasive melanoma phenotype is coupled with increased ferroptosis vulnerability. However, the regulatory circuits controlling ferroptosis susceptibility across melanoma cell states are unknown. In this work, we identified Apolipoprotein E ( APOE ) as the top lipid-metabolism gene segregating the melanoma MITF high /AXL low proliferative/ferroptosis-resistant from MITF low /AXL high invasive/ferroptosis-sensitive state. Mechanistically, ApoE secreted by the MITF high /AXL low cells protects the invasive phenotype from ferroptosis-inducing agents by reducing the content of peroxidation-prone polyunsaturated fatty acids and boosting GPX4 levels both in vitro and in vivo. Whole-exome sequencing indicates that APOE high expression in patients with melanoma is associated with resistance to ferroptosis, regardless of APOE germline status. In aggregate, we found a ferroptosis-resistance mechanism between melanoma cell states relying on secreted ApoE and APOE high expression as a potential biomarker for poor ferroptosis response in melanoma.
- 18 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (42) , eadp6164
Open AccessSecreted Apoe rewires melanoma cell state vulnerability to ferroptosis
A major therapeutic barrier in melanoma is the coexistence of diverse cellular states marked by distinct metabolic traits. Transitioning from a proliferative to an invasive melanoma phenotype is coupled with increased ferroptosis vulnerability. However, the regulatory circuits controlling ferroptosis susceptibility across melanoma cell states are unknown. In this work, we identified Apolipoprotein E ( APOE ) as the top lipid-metabolism gene segregating the melanoma MITF high /AXL low proliferative/ferroptosis-resistant from MITF low /AXL high invasive/ferroptosis-sensitive state. Mechanistically, ApoE secreted by the MITF high /AXL low cells protects the invasive phenotype from ferroptosis-inducing agents by reducing the content of peroxidation-prone polyunsaturated fatty acids and boosting GPX4 levels both in vitro and in vivo. Whole-exome sequencing indicates that APOE high expression in patients with melanoma is associated with resistance to ferroptosis, regardless of APOE germline status. In aggregate, we found a ferroptosis-resistance mechanism between melanoma cell states relying on secreted ApoE and APOE high expression as a potential biomarker for poor ferroptosis response in melanoma.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
Although numerous epigenetic aberrancies accumulate in melanoma, their contribution to initiation and progression remain unclear. The epigenetic mark 5-hydroxymethylcytosine (5hmC), generated through TET-mediated DNA modification, is now referred to as the sixth base of DNA and has recently been reported as a potential biomarker for multiple types of cancer. Loss of 5hmC is an epigenetic hallmark of melanoma, but whether a decrease in 5hmc levels contributes directly to pathogenesis or whether it merely results from disease progression–associated epigenetic remodeling remains to be established. Here, we show that NRAS-driven melanomagenesis in mice is accompanied by an overall decrease in 5hmC and specific 5hmC gains in selected gene bodies. Strikingly, genetic ablation of Tet2 in mice cooperated with oncogenic NRASQ61K to promote melanoma initiation while suppressing specific gains in 5hmC. We conclude that TET2 acts as a barrier to melanoma initiation and progression, partly by promoting 5hmC gains in specific gene bodies.Significance:This work emphasizes the importance of epigenome plasticity in cancer development and highlights the involvement of druggable epigenetic factors in cancer.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
Although numerous epigenetic aberrancies accumulate in melanoma, their contribution to initiation and progression remain unclear. The epigenetic mark 5-hydroxymethylcytosine (5hmC), generated through TET-mediated DNA modification, is now referred to as the sixth base of DNA and has recently been reported as a potential biomarker for multiple types of cancer. Loss of 5hmC is an epigenetic hallmark of melanoma, but whether a decrease in 5hmc levels contributes directly to pathogenesis or whether it merely results from disease progression–associated epigenetic remodeling remains to be established. Here, we show that NRAS-driven melanomagenesis in mice is accompanied by an overall decrease in 5hmC and specific 5hmC gains in selected gene bodies. Strikingly, genetic ablation of Tet2 in mice cooperated with oncogenic NRASQ61K to promote melanoma initiation while suppressing specific gains in 5hmC. We conclude that TET2 acts as a barrier to melanoma initiation and progression, partly by promoting 5hmC gains in specific gene bodies.Significance:This work emphasizes the importance of epigenome plasticity in cancer development and highlights the involvement of druggable epigenetic factors in cancer.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
DhmR and gene expression related to Fig1
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
DhmR and gene expression related to Fig1
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Suppl Table S4 from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
Diff gene expression between melanoma tet2+/+ and tet2lox/lox
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S4 from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
Diff gene expression between melanoma tet2+/+ and tet2lox/lox
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype
Supplementary Figures. Supplementary Figure S1: Zeb2-wildtype cells outcompete Zeb2-negative cells in terms of expansion and differentiation. Supplementary Figure S2: Zeb2 does not accelerate melanoma development on a p53-wildtype background. Supplementary Figure S3: ZEB2 affects the phenotypical switch between proliferation and invasion in mouse and human melanoma cells. Supplementary Figure S4: ZEB2 affects the phenotypical switch between proliferation and invasion in human melanoma. Supplementary Figure S5: TGF-ß treatment mediates the switch from ZEB2 to ZEB1 and induces an invasive gene signature.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype
Supplementary Figures. Supplementary Figure S1: Zeb2-wildtype cells outcompete Zeb2-negative cells in terms of expansion and differentiation. Supplementary Figure S2: Zeb2 does not accelerate melanoma development on a p53-wildtype background. Supplementary Figure S3: ZEB2 affects the phenotypical switch between proliferation and invasion in mouse and human melanoma cells. Supplementary Figure S4: ZEB2 affects the phenotypical switch between proliferation and invasion in human melanoma. Supplementary Figure S5: TGF-ß treatment mediates the switch from ZEB2 to ZEB1 and induces an invasive gene signature.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Suppl Table S3 from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
DhmR and gene expression tet-/- related to Fig3
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S3 from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
DhmR and gene expression tet-/- related to Fig3
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
Histological examination of samples, mC measurement by Mass Spec, survival curves showing the effect of p16Ink4 deletion, qPCR of hmC-related enzymes and melanoma related genes, hmedIP-pcr confirmation of hmedIP-seq, list of primers
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
Histological examination of samples, mC measurement by Mass Spec, survival curves showing the effect of p16Ink4 deletion, qPCR of hmC-related enzymes and melanoma related genes, hmedIP-pcr confirmation of hmedIP-seq, list of primers
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Legend of supplementary data from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
Description of supplementary tables and figures
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessLegend of supplementary data from TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression
Description of supplementary tables and figures